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The recent renaissance of psychedelic science has reignited 
interest in the similarity of drug-induced experiences to 
those more commonly observed in psychiatric contexts such 
as the schizophrenia-spectrum. This report from a multidis-
ciplinary working group of the International Consortium on 
Hallucinations Research (ICHR) addresses this issue, put-
ting special emphasis on hallucinatory experiences. We re-
view evidence collected at different scales of understanding, 
from pharmacology to brain-imaging, phenomenology 
and anthropology, highlighting similarities and differ-
ences between hallucinations under psychedelics and in the 
schizophrenia-spectrum disorders. Finally, we attempt to in-
tegrate these findings using computational approaches and 
conclude with recommendations for future research.
Key words:  psychedelics/psychosis/hallucinations/seroto
nin/Bayesian/computational
Introduction
Hallucinations, that is, percepts without corresponding 
stimulus, are common in psychiatric disorders (eg, 
schizophrenia spectrum disorders, a heterogeneous cat-
egory with variable course and expressions; henceforth 
SCZs), in neurological disorders (eg, Parkinson’s dis-
ease, Lewy body dementia), while they can be observed 
in the general population too. They are also engendered 
by psychotomimetic drugs, including serotonergic agon-
ists (ie, psychedelics). Since the nineteenth century, sci-
entists have posited that clinical and pharmacological 
experiences could be related and that psychedelics might 
constitute a model of psychosis.1 The discovery of ly-
sergic acid diethylamide (LSD) in 1943 was a boon to this 
“model psychosis theory,” spurring researchers to under-
stand psychosis by administering psychedelics to healthy 
volunteers and by self-experimentation.2,3
The recent revival of  psychedelic science generated 
new data and ideas, sparking great interest in the rele-
vance of  those compounds to psychosis. Do psychosis-
related and drug-induced hallucinations share a similar 
etiology? Do they involve similar or overlapping neural 
mechanisms? How similar or different are these experi-
ences phenomenologically and how are they each af-
fected by culture?
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Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An 
Interdisciplinary and Multiscale Comparison
This review from the International Consortium on 
Hallucinations Research (ICHR) aims to compare and 
contrast hallucinations under psychedelics with those ob-
served in SCZs. Our working-group adopted a multiscale 
approach spanning multiple levels of understanding. 
First, we reviewed the underlying neural mechanisms, 
with a special focus on microscopic (synaptic) and mac-
roscopic (network) mechanisms. Then, we described the 
subjective features of the two experiences, emphasizing 
their commonalities and differences and the impact of 
cultural factors. Finally, we described how computational 
models might connect these levels of analysis, from syn-
apses to society.
Pharmacology
At the synaptic level, SCZs has been linked to do-
paminergic (DA) alterations, while classical psyche-
delic drugs, such as LSD, mescaline, and psilocybin, 
are serotonin (5-HT) receptor agonists. Psychedelics 
can be divided into three main structural classes: 
phenethylamines, tryptamines, and ergolines. The 
phenethylamines are relatively selective for 5-HT2 sub-
types, whereas the tryptamines bind to a larger number 
of  sites, including most 5-HT receptors and σ 1 sites. 
Ergolines, by contrast, are even less selective and in-
teract with serotonergic, dopaminergic, adrenergic, 
and histaminergic receptors. There is now a consensus 
that the 5-HT2A receptor is the primary target for sero-
tonergic hallucinogens in the brain. The first evidence 
linking the 5-HT2A receptor to hallucinogenesis was de-
rived from animal behavioral models (see table 1). For 
example, Glennon and colleagues found that 5-HT2A 
antagonists, such as pirenperone and ketanserin, block 
the effects of  psychedelics in drug discrimination (DD) 
studies conducted in rats.4 Those investigators also 
found that the potencies (ED50 values) of  hallucinogens 
in the DD paradigm are robustly correlated with their 
5-HT2A affinity.
5 The head-twitch response (HTR) assay 
is another behavioral paradigm that has been used in 
mechanistic studies of  serotonergic hallucinogens. The 
HTR is a rapid reciprocal head movement that occurs in 
rodents after administration of  serotonergic hallucino-
gens.6,7 Similar to the DD paradigm, selective 5-HT2A 
receptor antagonists such as M100907 also block the 
HTR induced by hallucinogens.8,9 Likewise, LSD and 
other hallucinogens do not induce the HTR in 5-HT2A 
knockout mice.10,11 The HTR paradigm has become in-
creasingly popular in recent years because it is one of 
the few behavioral effects produced by hallucinogens 
that are not observed when animals are treated with 
non-hallucinogenic 5-HT2A agonists such as lisuride, 
an LSD analog.10,12,13 There is also a robust correlation 
between the ED50 values of  hallucinogens in the HTR 
paradigm and their potencies in humans and rat DD 
studies.7 Therefore, although the HTR assay does not 
directly model the psychedelic effects produced by hal-
lucinogens, it serves as a behavioral readout of  5-HT2A 
receptor activation that has considerable cross-species 
translational relevance.
In addition to DD and HTR, several other behavioral 
paradigms are commonly used to study the effects and 
pharmacology of  hallucinogens in rodents. Prepulse in-
hibition (PPI) of  the startle reflex is one example. PPI 
refers to the phenomenon where a weak prestimulus will 
inhibit the response to a subsequent startle-inducing 
pulse. This effect is commonly used as an operational 
measure of  sensorimotor gating. LSD and other hallu-
cinogens inhibit PPI in rats, an effect that can be blocked 
by pretreatment with selective 5-HT2A receptor antag-
onists (eg, M100907 and MDL 11,939).11,14 Although 
lisuride also reduces PPI in rats, its effect is blocked by 
DA D2/3 receptor antagonists but not by MDL 11,939. 
Similar findings have also emerged from studies of  ex-
ploratory behavior in rats. Although hallucinogens 
reduce exploratory locomotor activity in a novel envi-
ronment via 5-HT2A receptor activation,
15,16 lisuride pro-
duces a qualitatively different behavioral profile similar 
to the effect of  DA receptor agonists.17 Hallucinogens 
also alter timing behavior in rats and mice via 5-HT2A 
receptor activation.18–20
Although the 5-HT2A receptor was first linked to the 
mechanism of action of  hallucinogens in 1984, it took 
more than a decade to generate relevant evidence in 
humans. In 1998, a clinical study conducted by Franz 
Vollenweider and colleagues confirmed that ketanserin 
can block the subjective effects of  psilocybin.21 The 
5-HT2A/D2 receptor antagonist risperidone can also 
block the subjective response to psilocybin, whereas the 
D2 antagonist haloperidol was not effective.
21 More re-
cently, similar findings were reported for LSD. Although 
there has been speculation that D2 receptor activation 
may contribute to the psychopharmacology of  LSD, 
ketanserin seems to have little effect on D2 sites but is 
capable of  blocking the subjective and neural response 
to LSD.22–24 Notably, it was also reported recently that 
the intensity of  the subjective response to psilocybin 
is correlated with the level of  central 5-HT2A receptor 
occupancy.25
Brain-Imaging Markers
At the network level, SCZs and psychedelics exhibit in-
teresting commonalities and differences. A  first line of 
work comes from fMRI capture studies which compare 
ON and OFF periods for hallucinations and detect the 
phasic neural changes associated with hallucinatory ON 
states. In SCZs, these studies suggest a role for modality-
dependent associative cortex overactivations during hal-
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associated with more vivid experiences.28 Interestingly, 
the onset of hallucinations has been found associated 
with various aberrant activation/deactivation patterns. 
Hyperactivity was found in the hippocampal complex, as 
well as within associative cortices related to the hallucina-
tory content, while the default-mode network was found 
concomitantly deactivated.28,31
Brain imaging studies conducted to explore psyche-
delic states did not try to specifically capture halluci-
natory events, but rather focused on neural changes in 
relation to sensory experiences during the psychedelic 
intoxication, making links with hallucinations more in-
direct. Regarding visual hallucinations (VH), a greater 
cerebral blood flow was measured in the visual cortex 
under LSD.32 Increased early visual activity but de-
creased processing in associative visual areas was also ob-
served after psilocybin administration,33 suggesting that 
a combination of enhanced early sensory and reduced 
associative processing may contribute to the psychedelic 
experience.23,34
The second contribution comes from large-scale neural 
connectivity analyses, based on functional connectivity 
(FC; correlations between signals measured in different 
brain areas that define intrinsic brain networks), and 
effective connectivity, namely the effect one neuronal 
system exerts over another. We first look at FC studies 
and then briefly look at selective changes in directed ef-
fective connectivity.
A well-replicated finding in healthy individuals is an an-
tagonistic activity between the default-mode resting-state 
network (DMN) and the task-related central-executive 
network (CEN).35–40 Some authors proposed that the or-
thogonality of these networks might break down in psy-
chotic states.41 A  functional disconnection between the 
nodes of the DMN and CEN might notably engender im-
paired self-monitoring as observed in SCZs42 and mani-
fest as weak anti-correlation between these intrinsic brain 
networks.
According to the triple-network theory,43 the antago-
nistic activity of these resting-state networks (DMN and 
CEN) putatively reflects competing modes of informa-
tion processing that may be regulated by the salience net-
work (SN).44 Recent experimental data using intracranial 
EEG reported temporal profiles of task-evoked activity 
compatible with the hypothesis of SN acting as a switch 
between the CEN and DMN.45 Impairments of the triple-
network was proposed broadly involved in psychopa-
thology,46–48 and more specifically in intrusive experiences, 
such as flash-backs,49 obsessive ideas,50 or hallucinations 
in SCZs.31 In this vein, it has been proposed that SN im-
pairments may reflect a disturbance in ascribing salience 
properly,51 while DMN instabilities seem to be a shared 
characteristic across multiple sensory domains in patients 
with hallucinations.41
Classical psychedelics also induce pervasive changes in 
network-dynamics that can generally be described as a 
transition from regularity to increased instability. The co-
herence of classical resting-state networks was found di-
minished (disintegrated), while FC of the primary visual 
cortex expanded—desegregated.32,52 In complement to its 
reduced activity-level, the DMN was found to potentially 
co-activate with the CEN, a phenomenon which may un-
derlie the reported confusion between internally and ex-
ternally generated mental contents.53 Analyzing global 
brain connectivity with fMRI after the administration of 
LSD and psilocybin also revealed an increased integra-
tion of sensory and somatomotor information together 
with a disintegration of information from associative 
networks.23,54 Additionally, a general decrease in directed 
FC, and concurrently an increase in undirected FC after 
the administration of LSD was observed using MEG im-
aging and may point to increased instability in psyche-
delic states.55
Another influential theory in SCZs is the thalamic 
filter hypothesis (wherein the thalamus gates sensory 
information to prevent the information overflow in the 
cortex56). Resting-state fMRI studies in patients at var-
ious stages of the illness showed that prefrontal–thalamic 
FC was decreased, while thalamic FC with somatosen-
sory and motor areas was strengthened during disease 
progression, in a manner that correlates with positive 
symptoms.57,58 However, findings regarding the exact re-
lationship between thalamocortical dysconnectivity and 
clinical symptoms are mixed.59
Thalamocortical connectivity was found altered in 
psychedelic states. Specifically, LSD was found to selec-
tively increase effective connectivity from the thalamus 
to certain DMN areas, while other connections are at-
tenuated.60 Furthermore, increased thalamic connectivity 
with the right fusiform gyrus and the anterior insula cor-
related with visual and auditory hallucinations (AH), 
respectively.61
In summary (see table 2), hallucinations relate more to 
associative network overactivations in SCZs, while they 
are linked with primary cortex overactivations under 
psychedelics. Second, in both cases, the experience is as-
sociated with reduced internal integration of functional 
networks, an enhanced correlation between internally 
and externally oriented networks as well as an impaired 
thalamocortical connectivity. This phenomenon may no-
tably blur the differentiation between self-generated and 
perceived mental contents.
Phenomenology
In terms of  the sensory modalities involved, AH are 
the most common modality of  hallucinations in SCZs, 
with a prevalence of  around 79%.62 AH are three times 
as frequent as VH, which have a mean prevalence of 
approximately 27%.62,63 The exact prevalence of  hallu-
cinations in other modalities is largely unknown, with 
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for olfactory hallucinations (6–26%), gustatory hal-
lucinations (1–31%), and somatic or tactile hallucin-
ations (4–19%).62,64,65 AH occur alone approximately 
half  of  the time,66,67 while hallucinations in other mo-
dalities almost never occur alone.66,68 Some studies re-
port that multimodal or “fused” hallucinations (MMH; 
eg, seeing a talking head)69 are highly prevalent in 
SCZs,65,70–72 whereas other reports suggest that these 
hallucinations are rare.73 By contrast, hallucinations in-
duced by 5-HT2A agonists occur primarily in the visual 
domain74 (a shared feature with neurological disorders, 
such as Parkinson’s disease and Lewy body dementia). 
Nevertheless, distortions of  body image, tactile hallu-
cinations, and auditory alterations are not uncommon, 
especially when hallucinogens such as DMT or psilo-
cybin are administered at high doses.75–77 Audio-visual 
experiences have frequently been reported, but whether 
they qualify as hallucinations (or synesthesias) is still 
debated.77 Olfactory and gustatory hallucinations are 
very rare in comparison, but have occasionally been 
reported.78 Synesthesia-like experiences are also very 
common with serotonergic hallucinogens79 but are un-
common in SCZs.63
With respect to the content of VH, serotonergic hallu-
cinogens induce both elementary (brightly colored geo-
metric form constants such as lattices, cobwebs, tunnels, 
and spirals)78 and complex hallucinations.74,76,80 Complex 
hallucinations are images of scenes or landscapes, often 
containing “ordinary” (humans, animals, artifacts, etc.) 
and “extraordinary” entities (chimeras, spirits, aliens, 
monsters, etc.). The prevalence of complex hallucinations 
increases with drug dose76,81 and as the psychedelic expe-
rience progresses over time.82 In SCZs, VH more often in-
cludes life-size images of faces, people, objects, or events, 
which may be bizarre or frightening. Typically, the hallu-
cinations experienced in SCZs are detailed, concrete, and 
well-anchored in space.83
A series of experiential changes often precede the onset 
of psychosis, including AH (for a review, see Refs. 84,85). 
The occurrence of these prodromal hallucinations often 
provokes intense emotions; they may be attributed to a su-
pernatural origin and viewed as a sign of a larger meaning 
or fate.86 Similarly, the VH induced by 5-HT2A agonists 
are often very meaningful and can be imbued with strong 
existential, metaphysical, and religious overtones.80,87–89
Psychosis is often accompanied by very rich and de-
tailed hallucinations that are experienced as vivid, real, 
and beyond volitional control.83,90 There may be pro-
found changes in attention, reality testing, and memory.91 
Although the hallucinations induced by 5-HT2A agonists 
can be extremely vivid and may even feel more real than 
everyday sensory experiences, insight about their etiology 
is typically preserved; in other words, reality testing is not 
impaired and subjects using hallucinogens can typically 
distinguish between drug effects and normal waking con-
sciousness.80,92,93 In contrast, in SCZs, hallucinations tend 
Table 2. Comparison of the brain-imaging markers of psychotic and serotonergic hallucinations
Schizophrenia Spectrum 5-HT2A Agonists Comparison
Major networks  
a)During rest  
b)During task
a) DMN hypoactivation  
Decreased connectivity within 
and (mostly) between RSN  
b) Lack of DMN suppression 
during tasks—decreased DMN 
and CEN anticorrelation
a) DMN hypoactivation  
Decreased connectivity  
within—increased connectivity 
between RSN  
Decreased DMN and CEN 
anticorrelation  
b) Not enough evidence
a) Partially similar  
Differences in changes in  
connectivity between RSN
Hallucinations  
a) Symptom capture  
b) Resting-state analysis
a) Activation of hippocampus 
and modality-specific  
secondary cortex with  
deactivation of DMN and  
activation of SN and CEN  
b) Thalamic connectivity with 
prefrontal cortex  
lowered—thalamic  
connectivity with  
somatosensory cortex  
increased
a) Not available  
b) Increased activity in primary 
visual areas—decreased  
activity in associative areas  
Preserved thalamic connectivity 
with DMN—increased thalamic 
connectivity with CEN
a) Directly incomparable—mostly 
primary cortices in psychedelics—
mostly associative cortices in 
SCZs
Link with experience AH altered resting-state  
connectivity in left  
temporal areas   
VH increased RS  
connectivity between visual  
cortex and amygdala in SCZs 
(AH and VH) 
VH / imagery expanded connec-
tivity and activity of V1—VH/
imagery correlated with CEN ac-
tivation
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to be more difficult to discriminate from every-day per-
ception. An important contributing factor is the contex-
tual differences between the two states: while psychotic 
episodes in SCZs occur recurrently and unpredictably, 
the psychedelic state is transient (the nature and preva-
lence of chronic perceptual abnormalities, such as acid 
flashbacks and the hallucinogen persisting perceptual 
disorder are still debated77,94), purposeful and voluntarily 
initiated, thus marked by a special sense of agency (see 
Anthropology section).
As summarized in table 3, psychotic and serotonergic 
hallucinations differ in many respects: most notably in the 
modalities involved in the types of hallucinatory objects, 
and in the reality status ascribed to hallucinations. Yet, 
some commonalities can also be identified, especially as 
regards the meaningfulness, the emotional significance, 
and the metaphysical/spiritual quality of hallucinations 
(cf. Ref. 95).
Anthropology
Both in relation to psychedelic use and SCZs pathology, 
anthropological studies reveal enormous cultural vari-
ation that would benefit from a more systematic study. 
Comparative anthropological studies show that some fea-
tures of the experiences induced by hallucinogenic plants 
and mushrooms are similar across cultures (eg, geometric 
VH), while others vary extensively cross-culturally (eg, 
subjective feeling tone, meaning, or content of the hal-
lucinations).96–98 Hallucinogenic substances such as sero-
tonergic plants and mushrooms have been traditionally 
employed in a variety of sociocultural purposes. For 
example, species of Anadenanthera and Virola, psilo-
cybin mushrooms, and peyote have been used for divin-
atory and healing purposes.99–106 Some of these plants 
have also been employed in initiation rituals.107,108 It is 
worth highlighting that these hallucinogens have also 
traditionally been used for “non-ritualistic” purposes, 
for instance, in warfare109,110 and hunting.111 Finally, as il-
lustrated by the case of “psilocybin mushrooms parties” 
held in Mexico, the pre-Columbian recreational use of 
these plants has been documented.112
Observing homogeneity in the features of the hallu-
cinations produced by psychedelics within the same cul-
ture, many ethnographers have defended a culturalist 
approach to psychedelic hallucinations.97,107,113–117 For in-
stance, terms such as “culturally influenced visions” 117 
or “stereotypic visions” 97 have been used to argue that 
cultural variables are significant in shaping the hallucino-
genic experience. Several candidates have been proposed 
to shed light on the vectors of this enculturation of the 
hallucinatory content: mythological and cosmological 
knowledge,118 kinship system and gender,118 iconographic 
representations,117 verbal exchanges and ritual inter-
actions.119,120 However, these factors, the underpinnings 
of their effectiveness, and the sensitivity of different psy-
chedelic substances to their effects require further study.
In the laboratory context, there have been few attempts 
to identify and experimentally manipulate nondrug 
variables in studies of serotonergic psychedelics (see 
Refs. 121,122 for an overview). In one exception, Studerus 
et  al123 analyzed data from 23 controlled experimental 
studies, concluding that: the personality trait of absorp-
tion (“openness to cognitive, perceptual, imagistic, and 
other experiences”), the state of mind immediately prior 
to drug intake and having had few psychological prob-
lems in the prior weeks, were most strongly associated 
with positive experiences, while emotional excitability, 
young age, and an equipment-heavy experimental set-
ting, were most strongly associated with negative ex-
periences. In the resurgence of clinical therapeutics, 
extra-pharmacological variables considered especially 
important for therapeutic outcomes include a safe and 
supported treatment space, bespoke therapeutic support 
Table 3. Comparison of the phenomenology of psychotic and serotonergic hallucinations
Schizophrenia Spectrum 5-HT2A Agonists Comparison
Sensory modalities Mainly AH (multimodal in  
some cases)
Mainly VH (multimodal in some 
cases)
Different
Content No geometric hallucinations   
Complex hallucinations  
(mostly ordinary entities)
Geometric hallucinations  
Complex hallucinations (ordinary 
and extraordinary entities)
Different





Reality monitoring/insight Poor reality monitoring  
and insight
Reality monitoring and insight  
often preserved
Different
Duration Recurrent psychotic episodes;  
they can last from several  
weeks to several months.  
Hallucinatory episodes during  
psychotic episodes can last several  
seconds or minutes; continuously 
present in some individuals.
Transient states, lasting a few  
hours.  
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from trusted guides and appropriate music to accompany 
psychedelic sessions.124–126
There has also been little cross-cultural research on 
variability in hallucinations in SCZs. Nuevo et  al127 
conducted a cross-country study of  prevalence of  hal-
lucinations finding high variability (eg, from 0.8% in 
Vietnam to 31.4% in Nepal), but did not analyze this 
further in order to uncover any potential cross-cul-
tural patterns or correlations between specific cultural 
factors and the phenomenology of  hallucinations. 
Luhrmann et  al128 compared AH in SCZs patients in 
the United States, India, and Ghana, arguing that the 
negative content of  AH varied according to culture. 
However, this was a qualitative, interview-based study, 
with small numbers, and groups were not compared 
or matched in terms of  co-attendant clinical variables. 
A  large number of  questions remain unanswered in 
terms of  what role culture may play in shaping hallu-
cinations (for more detail, see Ref. 129). The relation-
ship between hallucinations and culture in SCZs and 
in the use of  psychedelics, and the possible overlap 
between these two research areas merits further study, 
not least because techniques traditionally mobilized 
to shape the phenomenology of  psychedelic hallucin-
ations in native societies in the Americas may enrich 
the therapeutic engagement with hallucinations in 
non-native contexts.130 This could be especially useful 
in cases where hallucinations respond minimally to an-
tipsychotic medication.
Computational Modeling
In previous sections, we described psychedelic experiences 
and contrasted them with psychotic experiences in SCZs. 
We notably focused on the potential neural mechanisms 
that may support those experiences, both at the level of 
synapses (pharmacology) and networks (brain-imaging). 
Then, we explored the first-person experience (phenom-
enology) and described how it can be shaped by the so-
cial and cultural milieu (anthropology). Despite such a 
multi-scale approach, our endeavor would be incomplete 
without discussing the links between them. Besides, an-
other relevant question remains open: Could hallucin-
ations with different phenomenology and neurobiology 
be underlain by (partially) similar mechanisms? To ad-
dress those questions, we turn to the burgeoning field of 
computational psychiatry131 and discuss how information 
processing might hold the key to both answers.
Computational models conceive the brain as an in-
formation processing system and provide normative ac-
counts of those processes, which are then mapped onto 
existing neural structures.131 We will focus on one partic-
ular type of computational models: Bayesian models.132,133 
The main idea behind this framework is that the brain 
learns generative models, that is, internal, hierarchical 
representations of the causal structure of the world.134,135 
When new inputs enter the system through the sensors, 
they are combined with prior information (accumulated 
knowledge which might include expectations, memories, 
Fig. 1. Illustration of different Bayesian models of hallucinations. (a–c) The predictive coding framework. (d–f) The circular inference 
framework. X, hidden cause; S, sensory variable; x and s, predictions and sensory messages; s-x, prediction error; k, relative weight of 
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etc.) to generate predictions about the causes of the sen-
sory input. In short, Bayesian models conceptualize the 
brain as an inference machine that tests multiple hypoth-
eses about the state of the world, the body or the brain it-
self  and picks the most probable one. We will summarize 
Bayesian theories that situate the synaptic disconnections 
implicit in the neuropharmacology of psychedelics (and 
hallucinations) in the larger context of abnormal func-
tional and effective connectivity studies reviewed above. 
The basic premise rests on linking false (perceptual) in-
ference to disconnections or disintegration of the psyche 
(in the sense of Bleuler), conceiving of hallucinations as 
aberrant perceptual inference due to abnormal belief  up-
dating, particularly in terms of how abnormal synaptic 
connectivity can lead to false inference via inappropriate 
weighting of sensory evidence and prior beliefs. This inap-
propriate weighting, via neuromodulation, could under-
write hallucinations in both SCZs and psychedelic states.
Inference can be implemented in various ways. 
According to predictive coding136 (ie, Kalman filtering137,138 
or variational free-energy minimization139), new sensory 
inputs are constantly explained-away by inhibitory feed-
back signals (sent from higher level areas to lower level 
areas, that “modulate” sensory inputs according to the 
behavioral context; ie, predictions; figure 1a). When pre-
dictions cannot fully explain the input, a residual error-
signal (ie, prediction error [PE]) is sent up in the hierarchy 
to update the dominant hypothesis (belief), thereby re-
ducing surprise (or surprisal). Conversely, when predic-
tions and inputs match, no PE is generated and thus, the 
current model is sustained. It is worth noting that, under 
certain formulations, surprise can also be minimized by 
appropriate action (active sampling of the environment, 
ie, active inference140), also explaining exploratory be-
havior and long-term minimization of PE.141 Crucially, 
both predictions and inputs are weighted according to 
their reliability (parameter k in figure 1; Kalman gain), 
resulting in precision-weighted PE. In one of the first ar-
ticles to suggest a computational account of psychedelics, 
Corlett and colleagues suggested that psychedelics act by 
increasing the prior weight (thus decreasing k), which re-
sults in inferences being mainly driven by expectations 
(figure 1b).142 The group also suggested a tentative neural 
mechanism for this prior overweighting, namely “exces-
sive AMPA-receptor signaling, in the absence of NMDA-
receptor impairment.” Importantly, it has been argued 
that the same mechanism might underlie hallucinations 
in SCZs,143–145 with a recent study validating this theory 
and, additionally, providing evidence for over-weighted 
priors in a group of nonclinical voice hearers.146 Taken to-
gether, those theories and evidence suggest that hallucin-
ations might reflect the same underlying computational 
mechanism, regardless of the exhibited phenomenology 
or clinical context.
The idea that serotonergic agonists increase prior 
weight is not unanimously accepted. In a recent article, 
Carhart-Harris and Friston suggested that the opposite 
might also be true, namely a relaxation of the priors that 
increases k (figure 1c).147 Their REBUS theory explains, 
among other things, the potential therapeutic effects 
of psychedelics (eg, in depressive disorders), mediated 
by a relaxation of pathological priors associated with 
those illnesses. Intriguingly, although the REBUS and 
the strong-prior theory seem at first sight incompatible, 
this is not necessarily true. In particular, priors, can be 
both over- and under-weighted, but at different levels in 
the cortical hierarchy, for example, weak low-level priors 
(high k) might be compensated by stronger high-level 
priors (low k).148
Although predictive coding is a powerful inference 
scheme, it is not the only one. For example, one could 
replace inhibitory priors with excitatory priors, resulting 
in a closely related algorithm in which beliefs are not up-
dated by error-signals, but by the sensory inputs per se 
(Belief  Propagation [BP]; figure  1d). Despite its gener-
ality and simplicity, BP postulates recurrent, excitatory 
connections. Without well-tuned control mechanisms 
(eg, inhibitory control), it results in information loops, 
a form of “run-away excitation” where beliefs are erro-
neously amplified and the feed-forward (input) and feed-
back (prediction) messages become aberrantly correlated 
(Circular Inference149,150). There are two types of loops: 
descending (overcounted priors; figure 1e) and ascending 
(overcounted inputs; figure  1f). Importantly, different 
loops result in different types of aberrant percepts: while 
ascending loops induce unimodal hallucinations (eg, 
AH in SCZs), descending loops give rise to multisensory 
phenomena (eg, synesthesia-like experiences; MMH in-
duced by DMT).151 Although the former link between 
ascending loops and SCZs has already been empirically 
established,152 the latter between descending loops and 
psychedelics remains purely theoretical and still needs ex-
perimental support.
Conclusion
In this article, we sought to compare and contrast hallu-
cinations in SCZs and under psychedelics. We identified 
several interesting common features: both experiences are 
related to a reduced integration and stability of functional 
networks, as well as a distorted anti-correlation between 
resting-state and task-positive networks. Furthermore, 
both experiences are afforded a strong metaphysical 
meaning. We also highlighted various crucial differ-
ences: First, psychedelics over-engage primary sensory 
cortices, hallucinations in SCZs, on the other hand, are 
mostly related to overactivation of associative networks. 
Furthermore, while drug-induced psychosis mostly en-
compasses VH (often geometric) with preserved in-
sight, SCZs is characterized by AH (mostly voices) and 
poor reality monitoring. Additionally, we pointed out a 
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particularly the role of serotonin in SCZs, the prevalence 
of MMH in both experiences and the potential cultural 
impact on hallucinations in SCZs. Finally, we suggested 
that psychotic experiences, regardless of their diagnostic 
categorization, might be underlain by the same compu-
tational mechanisms that tie together subjectivity and 
neural implementation, namely altered predictive proc-
essing. Future studies will have to clarify whether the 
same (eg, strong priors) or different (eg, climbing vs de-
scending loops) impairments underscore these different 
psychotic experiences.
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